/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Design Therapeautics, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$9.12 0.0928(9.28%) DSGN at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 9.07
Highest Today 10
Today’s Open 9.5
Prev. Close 8.94
52 Week High 10.00
52 Week Low 2.60
Day’s Range: Low 9.07 High 10
52-Week Range: Low 2.60 High 10.00
1 day return -
1 Week return +3.82
1 month return +56.91
3 month return +59.73
6 month return +138.63
1 year return +52.97
3 year return -28.55
5 year return -
10 year return -

Institutional Holdings

SR ONE CAPITAL MANAGEMENT, LP 11.46

Logos Global Management LP 7.41

BlackRock Inc 4.21

Point72 Asset Management, L.P. 3.17

TANG CAPITAL MANAGEMENT LLC 3.13

Baker Bros Advisors LP 3.01

Almitas Capital LLC 2.69

Vanguard Group Inc 2.58

Driehaus Capital Management LLC 1.89

Kynam Capital Management, LP 1.81

FMR Inc 1.67

Citadel Advisors Llc 1.48

Fidelity Select Biotechnology 1.45

Geode Capital Management, LLC 1.39

Vanguard Total Stock Mkt Idx Inv 1.38

Woodline Partners LP 1.37

iShares Russell 2000 ETF 1.29

State Street Corp 1.26

MPM Oncology Impact Management LP 0.97

D. E. Shaw & Co LP 0.69

Northern Trust Corp 0.64

Fidelity Small Cap Index 0.56

Dimensional Fund Advisors, Inc. 0.55

Vanguard Institutional Extnd Mkt Idx Tr 0.52

Renaissance Technologies Corp 0.47

iShares Russell 2000 Value ETF 0.46

iShares Biotechnology ETF 0.31

Fidelity Extended Market Index 0.28

Vanguard Russell 2000 ETF 0.27

Schwab US Small-Cap ETF™ 0.24

State St Russell Sm Cap® Indx SL Cl I 0.22

Bridgeway Ultra-Small Company 0.20

Nuveen Equity Index R6 0.16

Fidelity Enhanced Small Cap ETF 0.15

NT R2000 Index Fund - NL 0.13

Schwab Small Cap Index 0.13

iShares Micro-Cap ETF 0.13

Bridgeway Ultra-Small Company Market 0.11

Fidelity Nasdaq Composite ETF 0.11

NT R2000 Index Fund - DC - NL - 3 0.11

Market Status

Strong Buy: 0

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 509.26 M

PB Ratio 2.5527

PE Ratio 0.0

Enterprise Value 305.60 M

Total Assets 252.09 M

Volume 957032

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:226000 0.2M, FY19:834000 0.8M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-72360000 -72.4M, FY22:-58617000 -58.6M, FY21:-35533000 -35.5M, FY20:-8280000 -8.3M, FY19:-2047000 -2.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-14589000 -14.6M, Q2/2025:-152000 -0.2M, Q1/2025:-159000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-151000 -0.2M

Quarterly Net worth Q3/2025:-16997000 -17.0M, Q2/2025:-19083000 -19.1M, Q1/2025:-17715000 -17.7M, Q3/2024:-13039000 -13.0M, Q2/2024:-11793000 -11.8M

Fund house & investment objective

Company Information Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Organisation Biotechnology

Employees 55

Industry Biotechnology

CEO Mr. Pratik Shah Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow